小说Thiazolidinedione Lobeglitazone,改善2型糖尿病患者非酒精脂肪肝:它的效力和预测因素与响应能力有关。

文章的细节

引用

复制到剪贴板

李YH,金正日JH,金老,金重,Rhee EJ,赵YM,李BW

小说Thiazolidinedione Lobeglitazone,改善2型糖尿病患者非酒精脂肪肝:它的效力和预测因素与响应能力有关。

J韩国医疗科学。2017年1月,32 (1):60 - 69。doi: 10.3346 / jkms.2017.32.1.60。

PubMed ID

27914133 (在PubMed

]

文摘

尽管迅速增加非酒精脂肪肝患病率(NAFLD)在2型糖尿病(T2D),一些治疗方法目前可用。我们研究了小说的肝脏影响thiazolidinedione噻唑烷二酮类),lobeglitazone (Duvie) T2D NAFLD患者。我们招募了drug-naive或metformin-treated T2D非酒精性脂肪肝患者进行多中心,前瞻性,非盲、探索性的临床试验。瞬态肝脏弹性成像(Fibroscan (R);Echosens,法国巴黎)和衰减参数控制(CAP)使用方法量化肝脏脂肪含量。五十帽值高于250 dB /患者治疗后每天0.5毫克lobeglitazone 24周。主要终点是帽子下降值,和二级端点包括血糖成分的变化,肝脏脂质和概要文件。Lobeglitazone-treated病人显示显著降低上限值(313.4 dB在基线和297.8 dB / m / m 24周;P = 0.016),不管血糖控制。Lobeglitazone改善HbA (1 c)值(7.41%(57.5毫米)和6.56%(48.2毫米); P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment.

DrugBank数据引用了这篇文章

药物

Lobeglitazone